



NOV 1 1991

# Memorandum

*Unconventional  
Therapy File*

Date October 31, 1991  
From Associate Director, Cancer Therapy Evaluation Program  
Subject Antineoplastons

To Bruce A. Chabner, M.D.  
Director, Division of Cancer Treatment

I thought you would be interested in this for several reasons:

1. Our Unconventional Cancer Treatment approach seems to be working well (thanks to Mike Hawkins).
2. Our on-site review process is working well (thanks to Dorothy Macfarlane).
3. Antineoplastons deserve a closer look. It turns out that the agents are well defined, pure chemical entities. They are relatives of Thalidomide with presumed good CNS penetration. We are working with DTEP on them. The human brain tumor responses are real.

We will keep you informed.

*Mike*

Michael A. Friedman, M.D.

*Mike  
why not test them in a  
Phase II trial*